CDK9-IN-8

• CAT Number: I019557
• CAS Number: 2105956-51-0
• Molecular Formula: C₃₁H₃₂FN₇O₃
• Molecular Weight: 569.63
• Purity: ≥95%
• IUPAC Name: 1-N-[4-[[7-cyclopentyl-6-(dimethylcarbamoyl)pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
• InChI: InChI=1S/C31H32FN7O3/c1-38(2)27(40)25-17-19-18-33-30(37-26(19)39(25)24-5-3-4-6-24)36-23-13-11-22(12-14-23)35-29(42)31(15-16-31)28(41)34-21-9-7-20(32)8-10-21/h7-14,17-18,24H,3-6,15-16H2,1-2H3,(H,34,41)(H,35,42)(H,33,36,37)
• InChIKey: KXUNYNZTSOIXMY-UHFFFAOYSA-N
• SMILES: CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F

CDK9-IN-8（Cat No.:I019557）is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), a key regulator of transcriptional control and RNA polymerase II activity. By targeting CDK9, this compound disrupts the transcription of genes involved in cell cycle progression and survival, making it a promising candidate in cancer therapy. Preclinical studies have demonstrated its efficacy in inhibiting tumor growth and enhancing sensitivity to other anticancer agents. Ongoing research is focused on its potential applications across various malignancies, as well as its role in modulating cellular responses to therapy and improving patient outcomes.

Reference

[1]. Li Y, et al. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate. Bioorg Med Chem Lett. 2017 Aug 1;27(15):3231-3237.